Agios Pharmaceuticals (NASDAQ:AGIO) Stock Breaks Below 200-Day Moving Average – Here’s Why

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s stock price passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $31.70 and traded as low as $29.80. Agios Pharmaceuticals shares last traded at $30.55, with a volume of 3,094,276 shares changing hands.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios said updated safety data showed no new cases of hepatocellular injury in sickle cell patients treated with mitapivat. The company remains confident in the drug’s benefit-risk profile, is launch-ready, and continues labeling discussions with the FDA. Agios FDA review update
• Positive Sentiment: An analyst view argued that the delay may not invalidate the bullish thesis because mitapivat demonstrated meaningful reductions in transfusion burden, despite mixed efficacy on pain-crisis endpoints. Seeking Alpha upgraded the stock, while HC Wainwright maintained a “buy” rating with a $55 price target. Agios sickle cell analysis
• Neutral Sentiment: Agios was expected to potentially beat estimates in its upcoming quarterly report, but the earnings preview provided no confirmed results or new operating data. Agios earnings preview
• Negative Sentiment: The FDA extended the PDUFA decision date for mitapivat’s sickle cell supplemental application by three months, from November 1, 2026, to February 1, 2027. The extension followed the agency’s request for additional information on whether a Risk Evaluation and Mitigation Strategy (REMS) is needed. The FDA classified Agios’ response as a major amendment, delaying a potential approval and launch timeline. Agios shares fall on FDA review extension
• Negative Sentiment: The REMS review raises concerns about possible safety-related prescribing restrictions and commercialization requirements. In addition, mitapivat did not meet the sickle-cell pain-crisis endpoint, increasing uncertainty around the breadth of its eventual label.
• Negative Sentiment: A recent pre-arranged sale by Chief Medical Officer Sarah Gheuens adds a modest negative sentiment signal, although the transaction was not identified as the primary reason for the selloff. Agios insider sale

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AGIO. JPMorgan Chase & Co. raised their price target on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. Truist Financial decreased their target price on Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. Royal Bank Of Canada upped their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $55.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Agios Pharmaceuticals Stock Performance

The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -4.36 and a beta of 0.63. The firm’s 50-day moving average price is $33.62 and its two-hundred day moving average price is $31.70.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The business had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -5.85 earnings per share for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 7,866 shares of the stock in a transaction on Monday, October 26th. The shares were sold at an average price of $37.69, for a total value of $296,469.54. Following the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at $2,059,570.05. This trade represents a 12.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 39,855 shares of company stock valued at $1,285,512. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently bought and sold shares of the company. Nykredit A S acquired a new position in Agios Pharmaceuticals during the second quarter worth about $26,000. Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $43,000. Integrated Wealth Concepts LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $47,000. Allworth Financial LP purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $73,000. Finally, Versant Capital Management Inc boosted its position in Agios Pharmaceuticals by 378.7% during the second quarter. Versant Capital Management Inc now owns 2,001 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 1,583 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.